Table 2.
Main reasons anticoagulant not used in males with CHA2DS2-VASc ≥2, and females with CHA2DS2-VASc ≥3
| Netherlands (N = 66) n (%) |
World (N = 11,630) n (%) |
|
|---|---|---|
| Alcohol abuse | 0 (0.0) | 48 (0.4) |
| Already taking AP for other medical condition | 3 (4.5) | 628 (5.4) |
| Patient refusal | 1 (1.5) | 911 (7.8) |
| Previous bleeding event | 2 (3.0) | 211 (1.8) |
| Taking medication contraindicated or cautioned for use with OAC | 1 (1.5) | 78 (0.7) |
| Other | 12 (18.2) | 1682 (14.5) |
| Unknown | 19 (28.8) | 4588 (39.4) |
| Physician’s choice | 28 (42.4) | 3484 (30.0) |
| Bleeding risk | 5 (7.6) | 836 (7.2) |
| Concern over patient compliance | 0 (0.0) | 412 (3.5) |
| Guideline recommendation | 0 (0.0) | 237 (2.0) |
| Fall risk | 0 (0.0) | 401 (3.4) |
| Low risk of stroke | 8 (12.1) | 677 (5.8) |
| Other | 15 (22.7) | 921 (7.9) |
AP Antiplatelet drug, OAC Oral anticoagulation